Form 8-K - Current report:
SEC Accession No. 0000950170-25-071386
Filing Date
2025-05-14
Accepted
2025-05-14 16:10:10
Documents
13
Period of Report
2025-05-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K clsd-20250514.htm   iXBRL 8-K 50967
2 EX-99.1 clsd-ex99_1.htm EX-99.1 124021
3 GRAPHIC img171462827_0.jpg GRAPHIC 23864
  Complete submission text file 0000950170-25-071386.txt   331842

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT clsd-20250514.xsd EX-101.SCH 24862
15 EXTRACTED XBRL INSTANCE DOCUMENT clsd-20250514_htm.xml XML 4719
Mailing Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005
Business Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005 678-270-3631
Clearside Biomedical, Inc. (Filer) CIK: 0001539029 (see all company filings)

EIN.: 452437375 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37783 | Film No.: 25945537
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)